Related Experiment Video
Updated: Aug 30, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
Fatty acid-binding protein 2 in inflammatory bowel disease: mechanistic insights and translational perspectives
Shuhang Zhong1, Kaishuo Lv2, Xiaoqing Liu2
1Department of Gastroenterology and Hepatology, People's Hospital of Jiaozuo City, Jiaozuo, Henan, China.
Abstract:
Fatty acid-binding protein 2 (FABP2) is an intestine-specific cytoplasmic lipid chaperone with a molecular weight of approximately 14-15 kDa that plays a pivotal role in the uptake, intracellular trafficking, and metabolism of long-chain fatty acids. Emerging evidence indicates that FABP2 is not only a sensitive biomarker of intestinal mucosal injury but also may contribute to the pathogenesis and progression of IBD, potentially through the modulation of PPARγ signaling pathway, although the underlying mechanisms require further investigation. This review systematically summarizes the structural and functional characteristics of the fatty acid-binding protein (FABP) family members, with particular emphasis on the biological features of FABP2. We discuss the involvement of FABP2 in multisystem diseases and highlight its specific relevance in IBD. Furthermore, we summarize current evidence regarding the potential molecular mechanisms by which FABP2 may influence IBD, including its possible roles in intestinal barrier dysfunction, lipid metabolism, gut microbiota-host interactions, and its potential contribution to the attenuation of intestinal inflammation, possibly through regulation proliferation and differentiation of intestinal stem cells. Although the biological investigations of FABP2 in inflammatory bowel disease (IBD) have yielded promising findings, its clinical translation is still confronted with challenges such as the precise assessment of disease activity and the development of safe and effective targeted therapeutics. Collectively, this review provides a comprehensive reference for researchers and clinicians in the IBD field, highlighting the well-supported role of FABP2 as a diagnostic biomarker while discussing its potential as a therapeutic target, an area that warrants further mechanistic and clinical investigation.
Related Concept Videos
Inflammatory Bowel Disease II: Ulcerative Colitis
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease III: Crohn's Disease
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
